While the presidential election could have a significant influence on the pharma sector, arguably more important is who gains control of Congress. A blue sweep that hands Biden the presidency and gives Democrats control over the Senate will likely expand the Affordable Care Act, but the degree of drug-pricing reform will depend on the strength of the Democratic majority.
Read the whole story on our sister site, Drug Discovery & Development